UGT2B7 Antibody - #DF12140

Fig. 4. YY1 can repress expression by regulating UGT2B7 transcription. (A and B) The protein expression levels of UGT2B7 in YY1-shRNA and YY1-OE cell models of MCF-7 cells and MDA-MB-231 cells. Three replicate experiments were performed, and the data are presented as mean ± S.E.M. and significant differences detected using T test. (C) Diagram shows three putative YY1 binding sites on the UGT2B7 promoter predicted using ISMAR and the mutated promoter sequences used in luciferase reporter assays. Luciferase reporter assays were conducted using 293T cells cotransfected with pcDNA. YY1 and the wild-type (Wt) or mutant UGT2B7 promoter constructs. Three replicate experiments were performed, and the data are presented as mean ± S.E.M. and significant differences detected using T test. (D) Co-IP of UGT2B7 and YY1 in MCF-7 cells and MDA-MB-231 cells. IgG was used as a control. The experiments were repeated three times. Co-IP of YY1 and UGT2B7 in MCF-7 cells and MDA-MB-231 cells. IgG was used as a control. The experiments were repeated three times. (E) ChIP-quantitative polymerase chain reaction analysis of UGT2B7 occupancy on the YY1 promoter region containing putative UGT2B7 binding site in YY1-shRNA and YY1-OE cell models of MCF-7 cells and MDA-MB-231 cells. Three replicate experiments were performed, and the data are presented as mean ± S.E.M. and significant differences detected using T test. (F-G) The protein expression levels of UGT2B7 in MMTV-PyMT mice at different stages was analyzed by Western blot and IHC. The data are presented as mean ± S.E.M. and significant differences detected using T test, n = 6. (H) The protein expression levels of UGT2B7 in breast cancer samples at different stages was analyzed by IHC. The data are presented as mean ± S.E.M. and significant differences detected using T test, n = 6. ***P < 0.001, **P < 0.01, *P < 0.05.